Abstract
In broad terms, there are three categories of effective systemic therapy for breast cancer: hormone therapy (SERMs, aromatase inhibitors, etc…), biologics (trastuzumab, bevacizumab, and small molecule TKIs with similar functions), and cytotoxic chemotherapy. While hormone therapy is a long-standing option, dating back more than a century, chemotherapy was a more recent development with notable successes in the past few decades. Biological therapies have proven impact on overall survival only among patients with HER2 positive breast cancer and an international dialogue continues on the issue of the value of bevacizumab and other anti-angiogenic agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
